TG Therapeutics said it is working to develop a subcutaneous (under-the-skin) version of relapsing MS therapy Briumvi.
TotalEnergies shares up premarket on expected increase in Q4 production, strong LNG and power results, weak downstream sector ...
TG Therapeutics' stock rose 15% since my November buy recommendation, driven by Briumvi's strong performance and strategic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback